Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine
MetadataShow full item record
Objective. The DTPw-HB/Hib pentavalent combination vaccine has been developed following recommendations of the World Health Organization for the introduction of hepatitis B (HB) and Haemophilus influenzae type b (Hib) vaccines into routine childhood vaccination programs. The objectives of this study were to: 1) analyze the immunogenicity and the reactogenicity of the DTPw-HB/Hib pentavalent combination vaccine in comparison to separate injections of DTPw-HB and Hib vaccines as primary vaccination in a group of children who had received a dose of HB vaccine at birth and 2) in the second year of life to assess the antibody persistence as well as the response to a DTPw-HB/Hib or DTPw/Hib booster. Methods. In the first part of the study (primary-vaccination stage), conducted in 1998-1999, we analyzed the immunogenicity and reactogenicity of the DTPw-HB/Hib combination vaccine in comparison to separate injections of DTPw-HB and Hib vaccines as primary vaccination at 2, 4, and 6 months of age in 207 Costa Rican children who had received a dose of HB vaccine at birth. Later, in the booster-vaccination stage of the study, in 1999-2000, in a subset of the children (69 toddlers, now 15-18 months old), antibody persistence was measured, and response to a DTPw-HB/Hib or DTPw/Hib booster was also assessed. Results. In both primary-vaccination groups, at least 97.5 percent of the infants reached protective levels of antibodies (seropositivity) against the antigens employed in the vaccines. The DTPw-HB/Hib pentavalent combination vaccine did not result in more local reactions than did the DTPw-HB vaccine alone, and, in terms of general reactions, there was no clinically significant difference between the combination or separate injections, and with the pentavalent vaccine having the benefit of needing one less injection. Nine months after the third dose of the primary-vaccination course, antibody persistence was similar in both groups, with over 93 percent of children still having protective/seropositive titers for Hib, HB, and tetanus and about 50 percent for diphtheria and Bordetella pertussis. At 15 months of age, virtually all the toddlers responded with a strong boost response to all the vaccine antigens, whether they received the DTPw-HB/Hib pentavalent vaccine or the DTPw/Hib vaccine as a booster. Both booster regimens were equally well tolerated, indicating that up to five... (AU)
Faingezicht, Idis,Avila-Aguerro, Maria Luisa,Cervantes, Yolanda,Fourneau, Marc,Clemens, Sue Ann Costa (2002) Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica;12(4) 247-257,oct. 2002. Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892002001000005&lng=en&nrm=iso&tlng=en
Showing items related by title, author, creator and subject.
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City Biswal, Shibadas; Mendez Galvan, Jorge Fernando; Macias Parra, Mercedes; Galan-Herrera, Juan-Francisco; Carrascal Rodriguez, Monica Belisa; Rodriguez Bueno, Esteban Patricio; Brose, Manja; Rauscher, Martina; LeFevre, Inge; Wallace, Derek; Borkowski, Astrid (2021-06-02)[ABSTRACT]. Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. ...
Recommendations for modernizing infant vaccination schedules with combination vaccines in Colombia and Peru Torres-Martinez, Carlos; Chaparro, Eduardo; Mariño, Ana-Cristina; Falleiros-Arlant, Luiza Helena; Camacho-Moreno, Germán; Castillo, María E; Garces, Carlos; Coronell, Wilfrido; Somocurcio, Roberto (2023-01-27)[ABSTRACT]. The objective of this article was to consider the vaccination challenges in Colombia and Peru and the role of pediatric combination vaccines in overcoming these challenges. Barriers to including new vaccines ...
Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean De la Hoz Restrepo, Fernando; Alvis Guzman, Nelson; De la Hoz Gomez, Alejandro; Ruiz, Cuauhtémoc (2017-12)[ABSTRACT]. Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and ...